Patients on the 4872 hour spacing protocol show ALT and AST normalization in 7080% of cases at 12 weeks, compared to 4050% with GLP-1 monotherapy
Ongoing Support & Tools Weight management is a lifelong process
It is well-established that a hyperinsulin state directly activates insulin growth factor receptors (IGF), specifically IGF-1, on keratinocytes and fibroblasts, provoking cell proliferation, resulting in the aforementioned cutaneous manifestations of AN (5,6)
Michael Smith, a leading sleep specialist, remarked, Zepbound offers a new avenue for patients struggling with weight-related OSA, enhancing their overall treatment outcomes. Proven Clinical Impact The clinical benefits of integrating Wespers technology with GLP-1 treatments like Zepbound have been impressive: 65% reduction in unnecessary clinical visits 10% greater improvement in Apnea-Hypopnea Index (AHI) scores Enhanced detection of treatment-emergent central sleep apnea Improved long-term treatment adherence This combination of data-driven sleep monitoring and GLP-1 therapy allows for a more comprehensive and effective treatment approach, ultimately leading to better health outcomes for patients
